Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  Sieswerda, Elske ^a   Van Dalen, Elvira C ^a   Postma, Aleida ^b   Caron, Huib N ^a   Kremer, Leontien C M ^a  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHRACYCLINE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DAUNORUBICIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; GROWTH HORMONE; INOTROPIC AGENT; PLACEBO; VASODILATOR AGENT;

CANCER MORTALITY; CANCER SURVIVOR; CARDIOTOXICITY; CHILDHOOD CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG UTILIZATION; HEALTH CARE COST; HEART FAILURE; HOSPITALIZATION; HUMAN; OVERALL SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

EID: 77950106489     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008011     Document Type: Review

References (37)

1. Abdulla 2006 Abdulla J, Pogue J, Abildstrom SZ, Kober L, Christensen E, Pfeffer MA, et al.Effect of angiotensin-converting enzyme inhibition on functional class in patients with left ventricular systolic dysfunction - a meta-analysis. European Journal of Heart Failure 2006;8(1):90-6.
2. CIBIS-II 1999 No authors listed. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353(9146):9-13.
3. Cohn 2001 Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. New England Journal of Medicine 2001;345(23):1667-75.
4. Colucci 2007 Colucci WS, Kolias TJ, Adams KF, Armstrong WF, Ghali JK, Gottlieb SS, et al.Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial. Circulation 2007;116(1):49-56.
5. Exner 1999 Exner DV, Dries DL, Waclawiw MA, Shelton B, Domanski MJ. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. Journal of the American College of Cardiology 1999;33 (4):916-23.
6. Foody 2002 Foody JM, Farrell MH, Krumholz HM. Beta-blocker therapy in heart failure: scientific review. JAMA 2002;287(7):883-9.
7. Ganame 2007 Ganame J, Claus P, Uyttebroeck A, Renard M, D'hooge J, Bijnens B, et al.Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients. Journal of the American Society of Echocardiography 2007;20(12):1351-8.
8. Garg 1995 Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273(18):1450-6.
9. Granger 2003 Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al.Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362(9386):772-6.
10. Higgins 2008 Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
11. Jong 2003 Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003;361(9372):1843-8.
12. Kay 2001 Kay JD, Colan SD, Graham TP Jr. Congestive heart failure in pediatric patients. American Heart Journal 2001;142(5):923-8.
13. Kremer 2002 Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voute PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Annals of Oncology 2002;13(6):819-29.
14. Lefrak 1973 Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32(2):302-14.
15. Lipshultz 1991 Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. New England Journal of Medicine 1991;324(12):808-15.
16. Lipshultz 2002 Lipshultz SE, Lipsitz SR, Sallan SE, Simbre VC, Shaikh SL, Mone SM, et al.Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. Journal of Clinical Oncology 2002;20(23):4517-22.
17. Lipshultz 2005 Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, et al.Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. Journal of Clinical Oncology 2005;23(12):2629-36.
18. Maggioni 2002 Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. Journal of the American College of Cardiology 2002;40(8): 1414-21.
19. McMurray 2003 McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al.Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362(9386):767-71.
20. Module CCG Kremer LCM, Van Dalen EC, Moher D, Caron HN. Childhood Cancer Group. In: The Cochrane Library, Issue 3, 2009. Chichester: Wiley-Blackwell. Updated quarterly.
21. NYHA 1994 The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th Edition. Boston, Mass: Little, Brown & Co, 1994.
22. Packer 1996a Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al.The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. New England Journal of Medicine 1996; 334(21):1349-55.
23. Packer 1996b Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, et al.Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996;94(11):2793-9.
24. Parmar 1998 Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
25. RevMan 2008 The Nordic Cochrane Centre. The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre. The Cochrane Collaboration, 2008.
26. Shaddy 2001 Shaddy RE. Optimizing treatment for chronic congestive heart failure in children. Critical Care Medicine 2001;29(10 Suppl): S237-40.
27. Shaddy 2007 Shaddy RE, Boucek MM, Hsu DT, Boucek RJ, Canter CE, Mahony L, et al.Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 2007;298(10): 1171-9.
28. Silber 2004 Silber JH, Cnaan A, Clark BJ, Paridon SM, Chin AJ, Rychik J, et al.Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology 2004;22(5):820-8.
29. SOLVD 1991 No authors listed. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. New England Journal of Medicine 1991;325(5):293-302.
30. SOLVD 1992 No authors listed. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. New England Journal of Medicine 1992;327(10):685-91.
31. Sorensen 2003 Sorensen K, Levitt GA, Bull C, Dorup I, Sullivan ID. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer 2003;97(8):1991-8.
32. Steinherz 1995 Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Medical and Pediatric Oncology 1995;24(6):352-61.
33. Van Dalen 2003 Van Dalen EC, van der Pal HJ, van den Bos C, Caron HN, Kremer LC. Treatment for asymptomatic anthracycline-induced cardiac dysfunction in childhood cancer survivors: the need for evidence. Journal of Clinical Oncology 2003;21(17):3377-8.
34. Van Dalen 2006 Van Dalen EC, van der Pal HJ, Kok WE, Caron HN, Kremer LC. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. European Journal of Cancer 2006;42(18):3191-8.
35. Von Hoff 1977 Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. American Journal of Medicine 1977;62(2): 200-8.
36. Waagstein 1993 Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, et al.Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993;342(8885):1441-6.
37. Wang 2003 Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 2003;108(8):977-82.